ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO239

Intravenous Ferric Carboxymaltose Is Efficacious and Safe in Management of Iron Deficiency Anemia Among Hemodialysis Patients

Session Information

Category: Anemia and Iron Metabolism

  • 202 Anemia and Iron Metabolism: Clinical

Authors

  • Imam, Mahmoud Hamada, Faculty of medicine,Benha University, Benha, Egypt
  • Shawki, Mohammed, Faculty of medicine,Benha University, Benha, Egypt
Background

Anemia has a high prevalence among hemodialysis patients. Therapy mainly includes erythropoietin (EPO) and iron supplementation. Ferric carboxymaltose is a recent intravenous iron that proved to be efficacious among nondialysis CKD patients with no data regarding its use among dialysis patients. The aim of this study is to assess the efficacy and safety of Ferric carboxymaltose among hemodialysis patients.

Methods

In this prospective randomized study, 104 patients on maintenance hemodialysis were recruited. Inclusion criteria included: anemia (hemoglobin less than 10 gm/dL) and inadequate iron status (ferritin level < 200 mg/dL and TSAT < 20%). Exclusion criteria included: patient received other forms of iron within the last 4 weeks or a patient has recent blood loss event.
Patients were randomized to receive either intravenous Ferric carboxymaltose (once weekly)or Iron Sucrose (three times weekly). Hemoglobin hematocrit, ferritin, and TSAT were recorded at baseline and after 4 and 8 weeks. The dose of EPO was kept the same as before the study for patients already on EPO and on a fixed initial EPO dose for naive patients. Adverse effects including pain at injection site, allergy, fever were documented. ANOVA test was performed to compare the means of hemoglobin and iron studies. Chi x2 test was performed to compare the frequency of adverse effects between the two groups. Linear regression analysis was done to assess the likelihood of response to IV Ferric carboxymaltose.

Results

The mean age of patients was 56.4 ± 12.2 years. Female patients were 46%. In the Ferric carboxymaltose group, the mean ferritin increased from 148 ± 34 to 634 ± 154 ng/mL (95% CI:
-527.07 to -444.92 ,p. value < 0.001 ). in Iron Sucrose group, mean ferritin increased from 134 ± 42 to 596 ± 112 ng/mL (95% CI: -491.8 to -432.12; p-value < 0.001). There was no significant difference in the increase in both ferritin and TSAT between the two groups. In addition, There was no difference in the frequency of adverse effects among the two groups.

Conclusion

Intravenous Ferric carboxymaltose is efficacious in restoring iron repletion with tolerable adverse effects.